Introduction
============

Cigarette smoking is the largest preventable cause of death worldwide. According to WHO, tobacco related death was five million people in the year 2008 and would reach 8 million a year by 2030. Currently, one person is killed every six seconds by tobacco ([@b1-ijph-41-1]).

The history of tobacco use is back to the time when Columbus's found some people in the New World using "strange leaves" of plant *Nicotina tobacum* ([@b2-ijph-41-1]). Current estimates suggest that almost one third of the world population smoke ([@b3-ijph-41-1]). Around 35% of men and 22% of women in developed countries smoke. These figures in developing countries are about 50% and 9%, respectively ([@b2-ijph-41-1]). About 84% of global smokers live in developing countries comprising about 1.3 billion people ([@b4-ijph-41-1]). In Iran, cigarette smoking was started in the Shah Abbas Safavi (1571 -- 1629) kingship era. It rapidly spread throughout the country and in 1937 the first cigarette factory with the capacity of producing 600 million cigarettes per year started to work ([@b5-ijph-41-1]). Currently, Iranian Tobacco Company, a governmental organization, with more than 10 divisions/manufactories throughout Iran, produces about 12 billion cigarette sticks per year. In addition almost same amount is legally imported. We recently showed that the prevalence rate of current and daily cigarette smoking in Iran is correspondingly 12.5% (23.4% males and 1.4% females; burden: 6.1 million) and 11.3% (21.4 males and 1.4 females; burden: 5.6 million). We also reported that the average number of cigarettes smoked daily by an Iranian smoker was 13.7 sticks ([@b6-ijph-41-1]). Subsequently it is estimated that roughly 30 billion cigarette sticks is consumed a year in Iran. Recent data in Iran shows 62% increase in the manufactured cigarette from the period of 2000--2004 to 2005--2009 ([@b7-ijph-41-1]). Globally, more than five trillion cigarettes are manufactured yearly. Although there is no exact assessment of the world cigarette marketing expenditures/incomes, it seems that the cigarette is the most marketed production. Considering that in the USA more than \$10 billion is spent yearly on tobacco trade, the market is certainly more pronounced in developing countries ([@b1-ijph-41-1]). Two third of the world's tobacco is produced in 5 countries- China, USA, India, Brazil and Turkey with more than 100,000 hectares devoted to growing tobacco ([@b1-ijph-41-1]). In Iran 10,000--100,000 hectares are probably devoted to tobacco agriculture ([@b2-ijph-41-1]).

Nonetheless, no systematic review is available on the situation of the smoking in Iran, probably because most of the reported data are published in Persian journals and are unavailable to the international readership. In this review, the authors intended to bring the light into the more hidden/unavailable part of the researches in the field of cigarette smoking in Iran. Furthermore, certain national/international studies were included in order to mention the smoking cessation programs designed worldwide to provide a direction for policy makers and future studies.

Methods
=======

We conducted an integrated review of the literature on tobacco use (i.e. smoking and cession smoking) and its related harms, focusing on Iranian population. Eighty three published Persian-language papers of all types until 2009 were collected by using IranMedex (index of 183 Iranian medical Journals; <http://www.iranmedex.com>) and Magiran (index of more than 1300 Iranian journals; <http://www.magiran.com>) databases using various combinations of the following terms: cigarette, smoking, smoking cessation, prevalence, history, side effects, and lung cancer. Reports of WHO were also searched and optionally employed. The studies concerning passive smoking or presenting the statistically insignificant side effects were excluded. The prevalence rate of daily cigarette smoking (which is mostly defined as consuming at least one cigarette stick per day) has been collected from the results of the included articles. The 95% confidence interval (CI 95%) of the prevalence rates as well as smoking health risk associated odds ratio(OR) and CI 95% of ORs were retrieved from the articles or calculated.

The results are presented in three main sections: first the summary of the prevalence studies; second, side effect studies; and finally the articles discussing the cession strategies in Iran.

Results
=======

Prevalence of daily cigarette smoking
-------------------------------------

The reported prevalence rates of the included studies are shown in [Table 1](#t1-ijph-41-1){ref-type="table"}. The target populations, sample sizes and the gender as well as time and location of the studies are also presented. Cigarette smoking in Iran has been studied mostly among specific communities such as high school and university students, whereas studies on smoking among various occupations and rural areas are limited, and seemingly the situation of smoking among men has been at the center of attention.

There are 3 studies which report the amount of cigarette smoking over the whole country Iran; the former study was conducted between 1991 and 1999. In 1991 the prevalence of smoking was reportedly 14.6%; and 11.7% in the 1999 ([@b8-ijph-41-1]). In second study conducted at 2005 the prevalence rate was 15.3% ([@b9-ijph-41-1]); and lastly in 2007 daily cigarette consumption was 11.3% (CI=95%=9.0--14.1) ([@b6-ijph-41-1]). In the view of 95% CIs there is no significant gap between the results of these studies. The observed differences are somehow due to various definitions of daily smoking especially between studies of 2005 and 2007.

In regard with geographical distribution, the prevalence rate of daily smoking among adults ranged from 5.9% (CI=95%=3.5%--8.3%) in Gonabad, northeastern of eastern, ([@b10-ijph-41-1]) to 50% (CI=95%=45.6%--54.4%) in Savejbelagh near Tehran the capital ([@b11-ijph-41-1]). Among men and women specifically available data suggests that Savejbelagh owns the highest rates with 38.5% (CI=95%=47.1%--56.1%) and 21.2% (CI=95%=2%--39.4%) respectively, whereas the lowest rates belong to women in Isfahan ([@b12-ijph-41-1]) and in Gonabad with 0.5% (CI=95%=0%--1%) and 12.9% (CI=95%=7.4%--18.5%), respectively ([@b10-ijph-41-1]).

Smoking rate among male students ranged from 2.3% (CI=95%=0.3%--4.3%) in Zahedan, the center of an eastern province ([@b13-ijph-41-1]) to 39.6% (CI=95%=36.8%--42.5%) in Tehran ([@b14-ijph-41-1]). Prevalence of smoking among female students was between 13% in Guilan, northern Iran, ([@b15-ijph-41-1]) and 0.4% (CI=95%=0%--0.9%) in Kerman located at the mid-eastern Iran ([@b16-ijph-41-1]).

Also some focused populations show high prevalence of smoking such as traumatic patients and patients suffering bladder carcinoma with the rate of 38% and 44.5%, respectively ([@b17-ijph-41-1], [@b18-ijph-41-1]).

Side effects of active cigarette smoking
----------------------------------------

The summary of smoking-related side effects and the ORs (95% CI) of smoking associated risks are presented in [Table 2](#t2-ijph-41-1){ref-type="table"}. We found 37 articles on smoking associated damages conducted in Iran from 1999 to 2009. There were studies which investigated the relation of smoking and health problems among students. In a study on university students, smoking was inversely linked to general health levels ([@b49-ijph-41-1]). Kelishadi et al. reported that the levels of LDL and HDL were respectively higher and lower among smoking students ([@b27-ijph-41-1]) and the mean systolic and diastolic pressures were higher among smoking population. Among studies focused on adult populations, in 2000 Azizi et al. documented that smokers had lower HDL levels than non-smokers, OR=2.57 (CI=95%=2.24--2.76) ([@b50-ijph-41-1]); their study included almost 9500 participants. Also, among 9632 individuals over 20, increased risk of dyslipidemia was found among smoking participants; OR was 1.30 (CI95%=1.13--1.5) ([@b51-ijph-41-1]). In a review the hazardous effect of smoking on risk of tuberculosis infection has been emphasized ([@b52-ijph-41-1]). Smoking during pregnancy was reported to be a significant risk factor for maternal and fetal untoward outcomes with OR=2.71 (CI95%=1.52--4.84) ([@b53-ijph-41-1]). Also oral and dental problems were reported among smoking individuals in a few studies ([@b56-ijph-41-1]). Risks of bladder cancer and infertility were also increased among cigarette smokers ([@b54-ijph-41-1], [@b55-ijph-41-1]).

Smoking cessation
-----------------

The available data on smoking cessation in Iran suggests that the prevalence of quitting daily smoking is 3.4% of whole population. This rate was higher among those aged 55--64 years, 7.9% ([@b6-ijph-41-1]).

We included the main conclusions of the 4 available studies on the smoking cessation methods in Iranian population along with some international suggestions in [Table 3](#t3-ijph-41-1){ref-type="table"}.

Discussion
==========

Our result is significant as a summary of internationally unavailable part of smoking related researches is Iran; nevertheless a reasonable level of uncertainty should be considered in terms of credibility for the studies published in internationally unavailable literature.

The prevalence of cigarette smoking in Iran ranges from 0.4% to 41% in various subpopulations, both extremes correspond to the adolescence and in students. The latest data of the prevalence of daily smoking in the whole country is 11.3% with no significant change from 1991 to 2008. Whilst we cannot conclude a generalized pattern for the prevalent smoking and particularly its geographical distribution, the summary of the studies gathered in [Table 1](#t1-ijph-41-1){ref-type="table"} could be helpful in somewhat retrospective way for the future studies and researchers. Obviously the males are the population requiring attention in addition to teenagers with smoking rates as high as 40% and 13% in male and female students in certain areas. Seemingly the smoking rate associates with the regional income westernized lifestyle highest in the central and northern provinces and lowest in the eastern and border provinces.

The reported smoking-related complications in Iran are comparable with studies elsewhere and a wide range of diseases possibly affecting every organ have been linked to smoking. Dyslipidemia, oral cavity and respiratory disorders / infections have been reflected mostly in Iranian studies. Considering these effects and smoking burden on health care system, increased tobacco production in Iran is a major obstacle for public health and challenge for policy makers.

The only way to reduce hazard risk in the smokers is the complete cessation. Unfortunately there are limited studies on the efficacy of smoking cessation strategies in Iran. Tobacco control program strategies should be on preventing initiation and fostering cessation. However, these are not attainable in many smokers. So, a comprehensive tobacco control program should also include methods to reduce risks in those individuals who continue to smoke ([@b84-ijph-41-1]). Smoking-cessation treatment consists of three phases: preparation, intervention, and maintenance. Preparation aims to increase the smoker's motivation to quit and to build confidence. Intervention can take certain methods or a combination of them to help smokers to achieve abstinence. Maintenance, including support, coping strategies, and substitute behaviors, is necessary for permanent abstinence ([@b85-ijph-41-1]).

The efficacy of different methods to quit smoking in Iran has been investigated in 4 studies. In the study by Shahrokhi and Kelishadi the strategy "Quit and win contest" has been reported as a successful program in Iran and the authors claimed that the quit rates of smoking individuals participating this strategy increased from 1998 to 2004. Quit and win contest was designed by WHO as an effective and low-cost cessation programs especially for low and middle income countries ([@b90-ijph-41-1]). Education and behavioral therapy had a significant role in the successfulness of smoking cessation ([@b89-ijph-41-1]). Also, the lighter smoking and attending clinical courses by smokers comprised the success to quit smoking ([@b91-ijph-41-1]). The effect of smoking cessation on improving hematological disorders attributed to smoking was underscored ([@b92-ijph-41-1]).

Many smokers stop smoking by themselves, but support with advice and information may be helpful to increase the success rate. Health education methods have been shown successful in changing smoking behavior ([@b86-ijph-41-1]). In the Cochrane review of five different forms of Nicotine Replacement Therapy ([@b87-ijph-41-1]), all were significantly effective compared to placebo. The result of some studies revealed that the role of education and behavioral therapy in implementing smoking cessation program is essential ([@b86-ijph-41-1], [@b88-ijph-41-1], [@b89-ijph-41-1]). In general literature, intervention methods are divided into two categories. First, unassisted methods: these include quitting "cold turkey"; gradually decreasing the number of cigarettes smoked per day; using low-tar or low-nicotine cigarettes; quitting with friends, relatives, or acquaintances; using special cigarette filters or holders; using over the counter products; or substituting with another tobacco product (snuff, chewing tobacco, pipes, or cigars). Second, assisted methods: these include attending a program or course for a fee, consulting a psychiatrist or psychologist, using hypnotherapy, acupuncture, or nicotine gum. The latter method is "assisted" because nicotine gum requires a prescription and the physician should provide cessation counseling with the gum.
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###### 

Prevalence of smoking among different populations studied so far in Iran

  **Group**                       **Location**    **Sample size**   **Male**             **Female**         **Total**             **Year**   **Reference**
  ------------------------------- --------------- ----------------- -------------------- ------------------ --------------------- ---------- ------------------
  Youth at the military service   Tehran          976               20.8(18.3--23.3)     \-                 \-                    1999       [@b19-ijph-41-1]
  Medical students                Arak            475               29.5(25.4--33.6)     \-                 \-                    1999       [@b20-ijph-41-1]
  Medical students                Shiraz          694               15.4(11.8--18.9)     0.7(0--1.6)        9.1(6.9--11.2)        2000       [@b21-ijph-41-1]
  Senior high school students     Tehran          4023              7.2(6--8.2)          1(0.6--1.4)        4(3.4--4.6)           2001       [@b22-ijph-41-1]
  Medical students                Yasuj           206               18.4(13.2--23.7)     \-                 \-                    2001       [@b23-ijph-41-1]
  High school students            Urmia           1096              12.1(10.2--14.1)     \-                 \-                    2001       [@b24-ijph-41-1]
  High school students            Rasht           1297              15(13.1--17)         \-                 \-                    2002       [@b25-ijph-41-1]
  University students             Tehran          1066              25.4(21.9--28.9)     5(3.1--7)          16.3(14.1--18.5)      2003       [@b26-ijph-41-1]
  High school students            Isfahan-Arak    1950              12.9(10.5--14.7)     4(2.8--5.2)        8.7(7.5--10)          2004       [@b27-ijph-41-1]
  Junior high school students     Shiraz          1132              2.5(1.6--3.4)        \-                 \-                    2004       [@b28-ijph-41-1]
  High school students            Tabriz          1000              12.6(10.5--14.7)     \-                 \-                    2004       [@b29-ijph-41-1]
  High school students            Tehran          1119              \-                   \-                 4.4(3.2--5.6)         2004       [@b30-ijph-41-1]
  High school student             Zahedan         475               2.3(0.3--4.3)        0.4(0--1.1)        1.3(0.3--2.3)         2004       [@b13-ijph-41-1]
  Medical students                Ardebil         1106              22.1(17.6--26.6)     1.2(0.5--2.1)      7.4(5.9--9)           2005       [@b31-ijph-41-1]
  High school students            Gilan           1950              25.9(24.0--27.8)     13(10.8--15.2)     20(18.2--21.8)        2007       [@b15-ijph-41-1]
  University students             Tehran          2297              39.6(36.8--42.5)     14.8(12.7--16.8)   24.2(22.7--25.7)      2008       [@b14-ijph-41-1]
  University students             Kerman          833               \-                   \-                 4.5(3--5.8)           2008       [@b32-ijph-41-1]
  University students             Kerman          1677              21.5(18.5--24.4)     2.4(1.4--3.4)      11(9.5--12.5)         2008       [@b33-ijph-41-1]
  High school students            Birjand         1233              3.9 (2.8--5)         \-                 \-                    2008       [@b34-ijph-41-1]
  Junior high school students     Kerman          860               2.3(0.7--3.9)        0.4(0--0.9)        1.2(0.4--1.9)         2008       [@b16-ijph-41-1]
  over 15                         National        26618             27.2(26.4--28)       3.4(3.1--3.7)      14.6(14.2--15)        1991\*     [@b8-ijph-41-1]
  over 15                         National        36475             23.9(23.3--24.6)     1.7(1.5--1.9)      11.9(11.5--12.2)      1990\*     [@b8-ijph-41-1]
  Adult (over 20)                 Yazd            2154              31.2(29.2--33.1)     \-                 \-                    2000       [@b35-ijph-41-1]
  Adult (over 15)                 Meibod          330               14.8(11.--18.7)      \-                 \-                    2000       [@b36-ijph-41-1]
  Adult (over 15)                 Fars province   1998              25.3(22.4--28.2)     1.2(0.6--1.9)      11.5(10.1--12.9)      2001       [@b37-ijph-41-1]
  Adults (19--25)                 Isfahan         1315              18.5(15.5--21.5)     0.5(0--1)          9.3(7.7--10.8)        2003       [@b12-ijph-41-1]
  Traumatic patients              Tehran          339               40.1(35.9--45.3)     \-                 \-                    2006       [@b17-ijph-41-1]
  Population of a rural area      Kerman          1670              33.5(30.4--36.7)     2.9(1.8--41)       18.5(16.6--20.3)      2006       [@b38-ijph-41-1]
  High school teachers            Rasht           582               20.4(17.2--23.7)     \-                 \-                    2005       [@b39-ijph-41-1]
  Patients with bladder cancer    Mashad          200               \-                   \-                 44.5(37.6--51.4)      2002       [@b18-ijph-41-1]
  Adults(18--84)                  Ahvaz           1600              \-                   \-                 30(28--33)            2002       [@b40-ijph-41-1]
  Adults (20--40)                 Gonabad         356               12.9(7.4--18.5)      1.7(0--3.6)        5.9(3.5--8.3)         2002       [@b10-ijph-41-1]
  Adults (over 15)                Tehran          11801             22(20.9--23.1)       2.1(1.8--2.4)      10.6(10--11.1)        2003       [@b41-ijph-41-1]
  Adults (over 20)                Rafsanjan       491               38.5(32.42--44.86)   9.9(6.53--14.45)   24.3(20.56--28.32)    2003       [@b42-ijph-41-1]
  Rural area                      North of Iran   310               \-                   \-                 17.15(13.12--21.82)   2004       [@b43-ijph-41-1]
  Soldiers                        Guilan          612               25.7(22.2--29.1)     \-                 \-                    2005       [@b44-ijph-41-1]
  Adults                          Savejbelagh     500               51.6(47.1--56.1)     21.2(2--39.4)      50(45.6--54.4)        2007       [@b11-ijph-41-1]
  Soldiers                        Tehran          385               14.3 (10.8--17.8)    \-                 \-                    2007       [@b45-ijph-41-1]
  Adults (15--64)                 National        84706             26.6(26.1--27)       4.2(4.1--4.4)      15.3(15.1--15.5)      2005       [@b9-ijph-41-1]
  Adults (over 15)                Bandar Abbas    1810              22.7(20--25.5)       0.9(0.3--1.5)      11.7(10.2--13.2)      2008       [@b46-ijph-41-1]
  Infertile couples               Tehran          684               19.9(15.7--24.1)     0.6(0--1.4)        10.2(8--12.5)         2008       [@b47-ijph-41-1]
  General practitioners           National        5140              \-                   \-                 16(15--17)            2007       [@b48-ijph-41-1]
  Adults (15--64)                 National        5278              21.4(19.2--23.8)     1.4(1--2)          11.3(9--14.1)         2007       [@b6-ijph-41-1]

The prevalence rates are% and 95% confidence limits in parentheses.

The studies are sorted by the study date (Not publication date).

###### 

Reported adverse effects of active cigarette smoking

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Sample size**         **Effects**                                                                        **OR (CI95%)**                                 **Year**   **Reference**
  ----------------------- ---------------------------------------------------------------------------------- ---------------------------------------------- ---------- ------------------
  206                     Oral mucosal lesions                                                               13.06(3.83--44.52)                             1999       [@b56-ijph-41-1]

  20                      Increased number and abnormalities in alveolar macrophages                         UA[\*](#tfn4-ijph-41-1){ref-type="table-fn"}   1999       [@b57-ijph-41-1]

  340                     Increased sperm morphological abnormalities                                        2.69(1.64--4.40)                               1999       [@b55-ijph-41-1]

  390                     Perforated peptic ulcer                                                            2.4                                            2000       [@b58-ijph-41-1]

  9514                    Decreased HDL level (\<35mg/dL)                                                    2.57 (2.24--2.76)                              2000       [@b50-ijph-41-1]

  150                     Increased dental plaques                                                           UA                                             2001       [@b59-ijph-41-1]

  200                     Dislipidemia, Increased carboxy hemoglobin level Atherosclerosis                   UA                                             2001       [@b60-ijph-41-1]

  120                     Depression                                                                         2.73 (1.00--7.44)                              2001       [@b61-ijph-41-1]

  20                      Dermal adverse effects                                                             UA                                             2001       [@b62-ijph-41-1]

  356                     Psychological disorders                                                            3.71 (1.36--10.09)                             2002       [@b10-ijph-41-1]

  200                     Bladder cancer initiation and progress                                             UA                                             2002       [@b54-ijph-41-1]

  140                     Hyperactivity of airways                                                           49.33(13.80--176.46)                           2002       [@b63-ijph-41-1]

  68                      Decreased IgM, IgG and IgA levels Increased IgE level                              UA                                             2002       [@b64-ijph-41-1]

  96                      Insulin resistance                                                                 UA                                             2002       [@b65-ijph-41-1]

  300                     Periodontal diseases                                                               4.66 (1.53--14.21)                             2002       [@b66-ijph-41-1]

  113                     Higher fatality of TB                                                              4.19 (1.75--10.1)                              2003       [@b67-ijph-41-1]

  384                     Increased risk of stroke                                                           1.85 (1.18--2.91)                              2003       [@b68-ijph-41-1]

  299                     Pigmentation of oral mucosa                                                        9.07 (4.13--19.97)                             2003       [@b69-ijph-41-1]

  96                      Increased insulin resistance                                                       UA                                             2003       [@b70-ijph-41-1]

  192                     Airway constriction                                                                UA                                             2003       [@b71-ijph-41-1]

  56                      Progression of asbestosis                                                          22.5 (2.7--187.6)                              2004       [@b72-ijph-41-1]

                          Increased LDL                                                                                                                     UA         

  1950                    Decreased HDL                                                                                                                     2004       [@b27-ijph-41-1]

  86                      Increased systolic and diastolic blood pressure Increased oxidative stress level   UA                                             2004       [@b73-ijph-41-1]

  Review of 17 articles   Increased risk of tuberculosis                                                     UA                                             2005       [@b52-ijph-41-1]

  710                     Increased female/male conception                                                   UA                                             2005       [@b74-ijph-41-1]

  46                      Increased hemoglobin and hematocrite                                               Non-achievable                                 2005       [@b75-ijph-41-1]

  146                     Delaying tibia fracture fusion                                                     UA                                             2005       [@b76-ijph-41-1]

  252                     Cataract                                                                           1.90(1.03--3.50)                               2005       [@b77-ijph-41-1]

  9632                    Dislipidemia                                                                       1.30 (1.13--1.5)                               2006       [@b51-ijph-41-1]

  534                     Coated tongue\                                                                     7.17 (4.48--11.48)\                            2006       [@b78-ijph-41-1]
                          Hairy tongue                                                                       41.10 (5.60--301.86)                                      

  4317                    Maternal and fetal untoward outcomes                                               2.71 (1.52--4.84)                              2007       [@b53-ijph-41-1]

  240                     Coronary artery disease                                                            2.47 (1.24--4.94)                              2007       [@b79-ijph-41-1]

  128                     TB infection                                                                       2.44 (1.97--4.96)                              2007       [@b80-ijph-41-1]

  200                     Cardiac arrhythmias after acute MI                                                 UA                                             2009       [@b81-ijph-41-1]

  220                     Decreased saliva                                                                   UA                                             2009       [@b82-ijph-41-1]

  100                     Short-term memory decline                                                          UA                                             2009       [@b83-ijph-41-1]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The prevalence rates are% and 95% confidence limits in parentheses.

Unavailable

###### 

Qualitative results of international cessation programs, (Ordered by the study date)

  **Publication date**   **Participants**                                                  **Result of cessation programs**                                                                                                      **Reference**
  ---------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------
  1985                   Pregnant women from public health maternity clinics of USA        More success of health education vs. standard clinic                                                                                  [@b86-ijph-41-1]
  1990                   Unites States adult smokers                                       More success of self-managed quitting vs. cessation programs                                                                          [@b84-ijph-41-1]
  1992                   Randomized placebo-controlled trial in a smoke clinic in london   Success of nasal nicotine spray                                                                                                       [@b93-ijph-41-1]
  1994                   Randomized placebo-controlled trial in a research clinic          Success of nicotine patch and mecamylamine                                                                                            [@b94-ijph-41-1]
  1999                   Female smokers of a behavioral-cognitive cessation program        Success of exercise involved cessation programs with less weight gain                                                                 [@b95-ijph-41-1]
  2000                   Cochrane review on hypnotherapy                                   No success of hypnotherapy                                                                                                            [@b96-ijph-41-1]
  2000                   Cochrane review on training                                       No strong evidence of the efficacy of training health personnel                                                                       [@b97-ijph-41-1]
  2002                   Cochrane review of 45 randomized trails                           More success of self-help materials vs. no intervention                                                                               [@b98-ijph-41-1]
  2002                   Cochrane systematic review of cessation programs                  No success of acupuncture                                                                                                             [@b99-ijph-41-1]
  2002                   Participants of the programs of first cessation clinic in Iran    Success of lighter smokers and attending clinical courses                                                                             [@b91-ijph-41-1]
  2003                                                                                     Importance of educational and behavioral therapy                                                                                      [@b89-ijph-41-1]
  2006                   Cochrane review of nursing interventions                          Success of nursing support                                                                                                            [@b88-ijph-41-1]
  2007                   Cochrane review of NRT trials                                     Success of 5 NRT programs (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) Nasal spray most effective   [@b87-ijph-41-1]
  2008                   4 quit and win campaigns in Isfahan                               Success of Quit and Win contest                                                                                                       [@b90-ijph-41-1]
  2009                   00                                                                Success of using bupropion with less weight gain and side effects                                                                     [@b100-ijph-41-1]
